Clinical Observation of Metformin Combined with Pioglitazone in the Treatment of Incipient Type 2 Diabetes
10.6039/j.issn.1001-0408.2016.12.16
- VernacularTitle:二甲双胍联合罗格列酮治疗初发2型糖尿病的临床观察
- Author:
Lihua XIE
- Publication Type:Journal Article
- Keywords:
Rosiglitazone;
Metformin;
Type 2 diabetes;
Incipient;
Efficacy;
Safety
- From:
China Pharmacy
2016;27(12):1629-1631
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the efficacy and safety of metformin combined with rosiglitazone in the treatment of incipi-ent type 2 diabetes. METHODS:160 patients with incipient type 2 diabetes were randomly divided into observation group and con-trol group. Based on the diet control and exercise therapy,control group was orally given 0.5 g Metformin hydrochloride tablet,3 times a day;observation group was additionally given 4 mg Rosiglitazone maleate tablet,once a day. They were treated for 24 weeks. Clinical efficacy,body mass index (BMI),fasting plasma glucose (FPG),total cholesterol (TC),triglyceride (TG),2 h postprandial glucose(2 h PG),glycated hemoglobin(HbA1c),fasting plasma insulin(FINS)level,insulin resistance index(HOMA-IR)and insulin sensitivity index(HOMA-IAI)before and after treatment,and incidence of adverse reactions in 2 groups were ob-served. RESULTS:The total effective rate in observation group was significantly higher than control group,the difference was statis-tically significant(P<0.05). Before treatment,there were no significant differences in the above-mentioned indexes(P>0.05). Af-ter treatment,BMI、FPG、TC、TG、2 h PG、HbA1c、FINS、HOMA-IR in 2 groups were significantly lower than before,FPG,2 h PG, FINS,BMI and HOMA-IR in observation group was lower than control group,HOMA-IAI was significantly higher than before, and observation group was higher than control group,the differences were statistically significant(P<0.05). There was no signifi-cant difference in the incidence of adverse reactions between 2 groups(P>0.05). CONCLUSIONS:The efficacy and improvement of glucose metabolism,insulin resistance and insulin sensitivity of rosiglitazone combined with metformin are superior to metformin alone in the treatment of incipient type 2 diabetes,with similar safety.
